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ABSTRACT 
Adenosine has broad activities in organisms due to the existence of multiple 
receptors, the differential adenosine concentrations necessary to activate these receptors 
and the presence of proteins able to synthetize, degrade or transport this nucleoside. All 
adenosine receptors have been reported to be involved in glucose homeostasis, 
inflammation, adipogenesis, insulin resistance, and thermogenesis, indicating that 
adenosine could participate in the process of obesity. Since adenosine seems to be 
associated with several effects, it is plausible that adenosine participates in the initiation 
and development of obesity or may function to prevent it. Thus, the purpose of this review 
was to explore the involvement of adenosine in adipogenesis, insulin resistance and 
thermogenesis, with the aim of understanding how adenosine could be used to avoid, treat 
or improve the metabolic state of obesity. Treatment with specific agonists and/or 
antagonists of adenosine receptors could reverse the obesity state, since adenosine receptors 
normalizes several mechanisms involved in obesity, such as lipolysis, insulin sensitivity 
and thermogenesis. Furthermore, obesity is a preventable state, and the specific activation 
of adenosine receptors could aid in the prevention of obesity. Nevertheless, for the 
treatment of obesity and its consequences, more studies and therapeutic strategies in 
addition to adenosine are necessary.  
 
Key words: adenosine; obesity; adenosine receptor; adipogenesis; insulin resistance; 
thermogenesis.  
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Abbreviations  
 
ADORA2B, adenosine A2B receptor gene; ATP, adenosine triphosphate; BAT, brown 
adipose tissue; BWA1433, 1,3-dipropyl-8-(p-acrylic) phenyl xanthine; C/EBPα, 
CCAAT/enhancer-binding protein alpha; C/EBPβ, CCAAT/enhancer-binding protein 
beta; C/EBPδ, CCAAT/enhancer-binding protein delta;cAMP, cyclic adenosine 3’,5’-
monophosphate; CX3CL1, chemokine (C-X3-C motif) ligand 1; FAS, fatty acid 
synthase; FFA, free fatty acids; FGF21, fibroblast growth factor 21; GLUT4, glucose 
transporter type 4; HFD, high-fat diet; HMEC-1, human vascular endothelial cell line 1; IL-
10, interleukin-10; IL-1β, interleukin-1 beta; IL-4, interleukin-4; IL-6, interleukin-6; IR, 
insulin receptor; IRS2, insulin receptor substrate 2; KLF4, Kruppel-like factor 4; KLFs, 
Kruppel like factors; LPL, lipoprotein lipase; MCP-1, monocyte chemoattractant protein-1;  
mRNA, messenger ribonucleic acid;Myf5-, myogenic factor 5 negative; Myf5, myogenic 
factor 5; Myf5+, myogenic factor 5 positive; Myh11, myosin heavy chain 11; NST, non-
shivering thermogenesis; Pax7+ paired box 7 positive; PET–CT, positron emission 
tomography combined with computed tomography; PGC1α, peroxisome proliferator-
activated receptor γ co-activator 1 α; PKA, protein kinase A; PPARγ, peroxisome 
proliferator-activated receptor gamma; PTP1, protein tyrosine phosphatase 1; SAT, 
subcutaneous adipose tissue; Sca-1+, stem cell antigen-1 positive;  SNS, sympathetic 
nervous system; ST, shivering thermogenesis; TNFα, tumor necrosis factor-α; UCP1, 
uncoupling protein 1; VAT, visceral adipose tissue; Vegfa, vascular endothelial growth 
factor A gene; WAT, white adipose tissue.  
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1. Introduction 
The nucleoside adenosine is an endogenous purine formed by and adenine and D-
ribose bound by a β-N9-glycosidic bond that is produced by the degradation of ATP, ADP 
and AMP. Produced in almost all mammalian cells, the extracellular adenosine 
concentration is highly regulated, and depend of ATP, ADP and AMP levels, CD73 and 
adenosine deaminase (ADA) enzymatic activity and the  nucleoside uptake transport 
capacity of the cell (Fernandez et al., 2013; Zabielska et al., 2015). The broad actions of 
adenosine are largely due to the existence of multiple receptors. However, the receptor 
expression, the adenosine concentration required for receptor activation, and the presence 
of proteins able to synthetize, degrade or transport this nucleoside are also important factors 
that regulate the actions of adenosine. Hence, it is possible to observe a dichotomous effect 
of adenosine in several tissues, where it can participate in a physiological and 
pathophysiological manner (Fredholm, 2014, 2010). The effects of adenosine are mediated 
by the A1, A2A, A2B and A3 receptors, which are G protein-coupled receptors that exhibit 
different expression patterns depending on the tissue and disease state (Koupenova & 
Ravid, 2013).  Regardless of their expression pattern, these adenosine receptors have been 
demonstrated to be involved in glucose homeostasis, inflammation, adipogenesis and 
insulin resistance (Crist et al, 2001; Csoka et al, 2014; Eisenstein et al, 2014). Thus, it is 
expected that adenosine could participate in obesity.  
Obesity is defined as the over-storage of lipids in adipose tissue that occurs when 
there is an imbalance between the energy intake and energy used (Shoelson et al, 2007). 
This phenomenon is associated with metabolic syndrome, which is characterized by 
multiple systemic complications including hypertension, dyslipidemia, diabetes mellitus 
and insulin resistance (Fernández-Sánchez et al, 2011; Ouchi et al, 2011). Since adenosine 
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seems to be associated with many different effects, it is possible that it not only participates 
in the obesity stage, but is also involved in the initiation of obesity, and it may have anti-
obesity activities as well. However, the role of this nucleoside in obesity is not well studied. 
During obesity, many metabolic alterations occur that can damage several organs, such as 
vascular, adipose, skeletal muscle or liver tissue, resulting in the dysfunction of these 
tissues (Pardo et al, 2015). Thus, we aim to explore the involvement of adenosine in this 
phenomenon before obesity occurs (i.e., adipogenesis) to avoid it and during obesity (i.e., 
insulin resistance) to treat it as well as to understand its potential as therapeutic target to 
improve the metabolic state (i.e., thermogenesis).  
 
2. Obesity 
Adipose tissue is considered a ‘master regulator’ of systemic energy homeostasis 
that is involved in the regulation of key metabolic organs, such as the liver, pancreas, 
kidney or skeletal muscle (Kusminski et al., 2016), and its dysfunction is associated with 
the disrupted metabolic homeostasis and insulin resistance seen in obesity. Because of this, 
approaches to treat the dysfunctional adipose tissue are arising as novel therapeutic 
strategies. 
There are three kinds of adipose tissue recognized in organisms: white adipose 
tissue (WAT), brown adipose tissue (BAT), and the recently described beige or “brown-in-
white” adipose tissue (Lidell et al., 2013; Wu et al., 2012). WAT is the major site of 
adipose depot and its main role is the storage of energy by adipocytes in the form of lipid 
droplets (Moseti et al, 2016). In a healthy state, this fat is released into the blood stream as 
free fatty acids (FFA), which are used as an energy source by several organs (Siersbaek et 
al, 2010). During fasting and exercise, lipolysis occurs, leading to the release of FFA and 
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glycerol into the blood stream. Meanwhile, in the postprandial state, adipocytes begin starts 
to store high levels of lipids and glucose in the form of triglycerides as an energy resource. 
Additionally, elevated amounts of insulin in the postprandial state increase glucose uptake 
and the inhibition of lipolysis, contributing to the storage of glucose as triacylglycerol 
(Summers et al, 1999). 
Despite its participation in glucose uptake, WAT is involved in the regulation of 
systemic insulin-induced glucose uptake sensitization through its function as an endocrine 
organ, secreting adiponectin, leptin or pro-inflammatory cytokines, such as tumour necrosis 
factor-α (TNFα), interleukin-6 (IL-6), or IL-1β, which are inducer of insulin resistance 
(McArdle et al., 2013). The hyperplasia (increased adipocyte number) and hypertrophy 
(increased adipocyte size) of this organ have been tightly related to obesity-associated 
metabolic alterations (McArdle et al., 2013). In this regard, adipogenesis plays an important 
role, and its dysregulation is considered to be one of the key events occurring in the first 
steps of obesity, promoting large adipocyte formation and excess fat storage, which induce 
the release of pro-inflammatory cytokines and the dysregulation of adipokine secretion 
(Ouchi et al, 2011). Thus, a novel pharmacological intervention could allow for the 
prevention of the increase adipose tissue by inhibiting adipogenesis, avoiding the 
hypertrophy of adipose tissue in obesity. In this matter, it has been shown that adenosine, 
through the activation of adenosine receptors, could play an important role in the 
modulation of these processes in obesity, regulating lipolysis, insulin sensitivity in key 
metabolic organs such as adipose, liver or skeletal muscle, and even adipogenesis.  
 
2.1 Adipogenesis 
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The process responsible for the increase in WAT formation is adipogenesis. This 
process includes several molecular events that induce changes in cell morphology and 
secretion molecules, generating a mature adipocyte containing lipid droplets (Moseti et al, 
2016). Several studies have shown that the main nuclear factor regulators of adipogenesis 
are peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding 
protein α (C/EBPα) (Gross et al, 2016; Lefterova et al, 2014; Rosen et al, 2000). Moreover, 
Rosen et al (2002) have shown that PPARγ is capable of promoting adipogenesis in 
cultured mammalian cells lacking C/EBPα, but C/EBPα was unable to promote 
adipogenesis in an immortalized line of fibroblasts lacking PPARγ. Nevertheless, C/EBPα-
deficient cells produce dysfunctional adipocytes with a low capacity to store lipid droplets 
(Wu et al, 1999), indicating that both nuclear factors are necessary for proper adipocyte 
function. During differentiation, the gene expression pattern in the cell continues to change, 
making it possible to classify early, intermediate and late markers, along with increased 
triglyceride accumulation (Gregoire et al, 1998). In response to high levels of glucose and 
fatty acids, the preadipocyte increases C/EBPβ and C/EBPδ expression in the early state 
(Siersbæk et al, 2014). This results in an increase in PPARγ and C/EBPα expression, 
leading to the intermediate state (Wu et al, 1999). Finally, when the preadipocyte is 
transformed into an adipocyte at the late state, it expresses specific markers, such as 
glucose transporter 4 (GLUT4), lipoprotein lipase (LPL) and fatty acid synthase (FAS) 
(Moseti et al, 2016). In the early state, one of the markers is the family of Kruppel-like 
factors (KLFs), of which isoform 4 (KLF4) has been characterized as an early marker of 
adipogenesis initiation (Birsoy et al, 2008) and whose expression seems to be crucial in this 
process (Birsoy et al, 2008). Interestingly, a recent study showed that KLF4 is essential in 
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the adipogenesis inhibition mediated by the A2B receptor activation (Eisenstein et al., 
2014). 
 
2.1.1 Role of adenosine in obesity-related adipogenesis  
Adipose tissue as an energy depository, in a positive energy balance, it is able to 
store energy as triglycerides, while in a negative energy balance (caused by exercise or 
fasting), it is responsible for degrading fat into FFA to be used as energy in the peripheral 
organs (Frühbeck et al, 2014; Rodriguez et al, 2015). However, as part of their endocrine 
function, adipocytes secrete adipokines capable of increasing insulin sensitivity (i.e., 
adiponectin) or insulin resistance (i.e., TNFα or resistin) (Blüher et al, 2014).  
Obesity presents an increase in fat mass related to hypertrophy and hyperplasia due 
to a high rate of adipogenesis (Hausman et al, 2001). Thus, this effect will produce an 
excess storage of fat and, in accordance with the function of adipose tissue as an endocrine 
organ, alterations in adipokines secretion, resulting in adipose tissue dysfunction (Rosen et 
al, 2000). These alterations included the secretion of monocyte chemoattractant protein-1 
(MCP-1) and TNFα, promoting a whole-body inflammatory state that is maintained over 
time, which is referred to as a chronic inflammation (Guilherme et al, 2008). 
It has been shown that adenosine is able to promote adipogenesis via activation of 
A1 receptor, but also to inhibit adipogenesis mediated by the activation of the A2B receptor 
in the preadipocyte (Gharibi et al, 2012). It has been reported that the A2B receptor is highly 
expressed in human primary preadipocytes in culture, and its activation reduces the 
transformation from preadipocytes to adipocytes (Eisenstein et al, 2014). This phenomenon 
seems to be mediated by KLF4, since the knock down of expression in stromal vascular 
cells from mouse adipose tissue inhibits this effect, indicating the existence of a novel A2B 
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receptor-KLF4 inhibition axis. However, it has been shown that an elevated adenosine 
concentration is necessary to activate this receptor (Fredholm et al, 2001; Patel et al, 2003); 
thus, it is likely that this receptor is not active until the concentration of adenosine is a high 
as it is during obesity, when the increased adipogenesis has already occurred. Supporting 
this hypothesis, adipose tissue from obese patients exhibits an increased expression of the 
ADORA2B gene, which encodes the A2B receptor (Johnston-Cox et al, 2012), that is highly 
correlated with KLF4 expression (Eisenstein et al, 2014). However, further investigation is 
necessary to evaluate if this could be a mechanism to ameliorate the increase in adipocytes 
during obesity or whether it is possible to revert this process. 
 
2.2  Role of adenosine in obesity-associated insulin resistance 
Substantial evidence shows that obesity is closely related with a state of insulin 
resistance (McArdle et al., 2013), which is considered to be a key step in the development 
of diabetes and metabolic syndrome (Ginsberg, 2000). Insulin resistance is characterized by 
low sensitivity and/or responsiveness to insulin by target organs and tissues (Hardy et al., 
2012; Savage et al., 2005), resulting in alterations in glucose uptake or metabolism. It has 
been reported that the insulin-dependent glucose uptake in a postprandial state is mainly 
dependent on GLUT4-mediated transport in skeletal muscle, which accounts for 
approximately 60-70% of the insulin-dependent glucose uptake in the body, and adipose 
tissue, which accounts for approximately 10% (Wilcox, 2005). However, though glucose 
uptake is not insulin-dependent in liver, this organ is responsible for approximately 30% of 
the insulin-mediated glucose disposal in the body, which occurs through insulin-regulated 
metabolic processes in the liver, such as glycogenesis, the inhibition of gluconeogenesis, 
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and releasing of glucose (Wilcox, 2005). Thus, it is typically thought that in an insulin-
resistant state, insulin actions on these tissues are altered.  
Several studies have demonstrated the existence of a relationship between adenosine 
and insulin. The activation of the A1 receptor has been shown to be related to insulin-
dependent glucose uptake in muscle, since reduced endogenous adenosine concentrations 
or the blockage of the A1 receptor decrease insulin-mediated glucose uptake (Thong et al, 
2007). Meanwhile, in endothelial cells treated with an A2A receptor antagonist, the 
increased L-arginine transport induced by insulin is blocked (Guzmán-Gutierrez et al, 
2016). Nevertheless, the effect of adenosine on insulin responsiveness is not quite clear, 
and its actions in the vascular bed have been recently well discussed (see review by Silva et 
al, 2016). Human studies on the use of non-selective antagonists of adenosine receptors 
(e.g., aminophylline or pentoxifylline) have shown that adenosine is involved in glucose 
homeostasis and insulin metabolism (Arias et al., 2001; Corssmit et al., 1994, 1996). 
Studies in animals support this finding and link adenosine with obesity-associated insulin 
resistance (Table 1). 
In rats with insulin resistance induced by obesity, the inhibition of adenosine 
receptors by the systemic administration of general antagonist (i.e., 8-phenyltheophylline 
and BWA1433) increased insulin sensitivity in muscle and liver (Challis et al., 1984; Crist 
et al., 2001, 1998), but reduced the insulin response in adipose tissue (Crist et al., 1998). 
Conversely, in lean mice the general activation of the adenosine receptors generates 
glucose intolerance (Figler et al., 2011). Thus, adenosine could be involved in alterations of 
insulin resistance and glucose homeostasis in obesity, generating differential effects on 
adipose tissue, skeletal muscle and liver likely due to the involvement of different 
adenosine receptors isoforms (Figure 1).  
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2.2.1.  Adipose tissue 
As discussed above, WAT is involved in the pathophysiology of insulin resistance, 
participating in systemic metabolic control. WAT is divided in different depositions zones, 
the main ones being the abdominal subcutaneous adipose tissue (SAT) and visceral adipose 
tissue (VAT). SAT is located in the lower parts of the body and is primarily involved in 
storage capacity, being considered important to the accumulation of triglycerides in periods 
of excess energy intake and to their release in periods of fasting, starvation or exercise 
(Bjørndal et al., 2011). On the other hand, VAT surrounds inner organs and is divided 
according to its localization in omental, mesenteric, retroperitoneal, gonadal and pericardial 
(Bjørndal et al., 2011). Since VAT has less insulin sensitivity than SAT, it does not respond 
to the anti-lipolytic insulin effect, increasing lipolysis and FFA plasma levels (Berg and 
Scherer 2005; Rodríguez et al. 2007). Moreover, VAT shows a higher secretion of pro-
inflammatory and proatherogenic factors, such as TNFα, IL-6, C reactive protein, 
angiotensinogen, plasminogen activator inhibitor-1 and vascular endothelial growth factor 
(VEGF), among others (Berg and Scherer 2005). Thus, VAT has been shown to be tightly 
related to the development of insulin resistance and metabolic syndrome (Bjørndal et al., 
2011; Hardy et al., 2012). 
WAT plays a central role in the control of systemic insulin resistance by regulating 
insulin sensitivity in other insulin target tissues, including skeletal muscle and liver, the two 
major organs involved in the control of glucose homeostasis (Hardy et al., 2012; Wilcox, 
2005). Mechanisms linking WAT and obesity-associated insulin resistance include the 
secretion of adipokines (i.e., adiponectin and leptin) and proinflammatory cytokines (i.e., 
TNFα, IL-6 or IL-1). Adiponectin is an insulin sensitizer whose secretion by VAT is 
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reduces in obesity, while leptin is also a sensitizer of insulin whose levels are increased in 
obesity but with reduced effects (Yadav et al., 2013). Meanwhile, TNFα, IL-6 or IL-1 have  
deleterious effects on insulin actions and are increased in obesity (Hardy et al., 2012; 
McArdle et al., 2013). On the other hand, insulin resistance itself and the expansion of 
VAT increases the release of FFA into the blood stream, and this increase generates the 
accumulation of triglycerides in other tissues such as skeletal muscle and liver, a 
phenomenon known as lipotoxicity, promoting insulin resistance and cardiovascular risk 
(Guilherme et al., 2008; Kahn and Flier, 2000; McArdle et al., 2013). Thus, the 
understanding of mechanisms regulating VAT in obesity seems to be relevant in elucidating 
the control of systemic insulin resistance. 
It has been shown that adipocytes from WAT express the A1, A3, A2A and A2B 
receptors (in order of abundance) (Gnad et al., 2014). Most studies in animal models of 
obesity have shown that the specific activation of the A1 receptor reduces obesity-
associated systemic insulin resistance (Dhalla et al., 2007; Schoelch et al., 2004), an effect 
that, according to specific KO or overexpression in obese mice, is ascribed mainly to WAT 
(Dong et al., 2001; Johansson et al., 2007).  
On the other hand, the treatment of obese rats with BWA1433, an antagonist that 
mainly inhibits the A1 and A2B receptors (LaNoue et al., 2000), showed that even though 
the systemic glucose homeostasis was improved (Xu et al., 1998), the insulin-induced 
glucose uptake in adipose tissue was impaired (Crist et al., 1998), an effect likely mediated 
by the inhibition of the A1 receptor, which is the adenosine receptor most highly expressed 
in WAT, as described above. It has been reported that in lean rats, adipocytes release 
adenosine spontaneously and, by both autocrine and paracrine processes, increase insulin 
signaling through A1 receptor activation (Takasuga et al., 1999). Along with this effect, a 
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higher adenosine concentration was found in adipose tissue from obese subjects (Kaartinen 
et al., 1991), which could be related to the increased activation of A1 receptor signaling 
observed in adipose tissue from patients with obesity and in obese rats (Berkich et al., 
1995; Kaartinen et al., 1991). Additionally, A1 receptor expression is reduced in SAT from 
obese patients (Kaartinen et al., 1991), an effect that could be due to desensitization in 
response to the higher extracellular adenosine concentrations. However, although the 
increase in this signaling pathway in obesity is likely due to increased local adenosine 
concentrations, as mentioned above, an altered insulin response in adipose tissue is still 
present (Crist et al., 1998; Dong et al, 2001), and this local increase of adenosine could be 
used to avoid the worsening of insulin resistance. Thus, the primary evidence shows that 
the increase of adenosine in obesity seems to help to reduce the deleterious effects of 
insulin resistance in obesity on adipose tissue through the activation of A1 receptor. 
Adenosine also participates in the regulation of adipocyte lipolysis exerting a potent 
anti-lipolytic effect through its interaction with the A1 receptor (Frühbeck et al. 2014). This 
activation reduced the synthesis of FFA in the adipocyte (Johansson et al, 2007). FFA is 
used as an important energy source during fasting, and its formation is inhibited by insulin 
(Dhalla et al, 2007). A1 receptor activation blocks lipolysis via the activation of an 
inhibitory G protein (Gi) and the subsequent inhibition of adenylate cyclase (Clifford et al., 
1998; Liang et al., 2002; Schoelch et al., 2004). Indeed, A1 receptor antagonism or the 
inhibition of Gi protein-coupled adenosine receptors (such us leptin or TNFα) can lead to 
an increased in lipolysis (Botion et al. 2001; G Frühbeck, Gómez-Ambrosi, and Salvador 
2001; Yang et al. 2009). Therefore, it is though that the increase of A1 receptor activity in 
obesity, probably induced by an increased adenosine concentration, alters the hormonal 
control of lipolysis, promoting the reduction in lipolysis and the higher gain weight in 
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obese rats (Berkich et al., 1995; Schoelch et al., 2004; Vannucci et al., 1989) and thus, 
contributing to the lipolysis inhibition induced by insulin. Furthermore, this phenomenon 
could explain why transgenic mice overexpressing the A1 receptor in adipose tissue and fed 
a high-fat diet (HFD) do not develop obesity-associated insulin resistance despite the 
presence of high body weight (Dong et al., 2001). Indeed, it has been determined that A1 
receptor expression in the adipose tissue of patients with obesity is inversely related to the 
ability to lose weight (Barakat et al., 2006; Johnson et al., 2001). Additionally, along with 
reduced lipolysis, the increased activity of the A1 receptor also increases glucose uptake by 
adipocytes, leading to increased triglyceride content in adipose tissue and increasing the 
likelihood of obesity (Leto and Saltiel, 2012). Thus, through A1 receptor activation, 
adenosine seems to play an important role in the excess weight gain seen in obesity, but its 
activation could improve systemic glucose homeostasis in obese patients (Figure 2). 
Furthermore, some researchers have proposed lipolysis inhibitors, such as A1 receptor 
antagonists, as a therapeutic target (Dalla et al, 2009). 
A2A receptor activity has also been shown to be involved in lipolysis. According to 
Gnad et al (2014), the specific activation of the A2A receptor increases lipolysis in 
adipocytes; moreover, the systemic activation of this receptor by a specific agonist in obese 
mice reduces WAT deposits, resulting in weight loss. Nevertheless, the predominance of 
lipolysis inhibition in obesity despite the increase in adenosine concentration might be due 
to the high expression of the A1 receptor and the inability to reach adenosine concentration 
necessary to activate the A2A receptor. This idea is supported by findings showing that 
increasing the adenosine concentration to over 1000 µmol/l in primary cultures of human 
white adipocytes or the overexpression of the A2A receptor in white adipocytes results in an 
increase in lipolysis (Gnad et al., 2014). 
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In addition, adenosine could be involved in the secretion of adiponectin and leptin, 
which are key molecules in systemic insulin sensitization. It has been reported that the 
activation of the A1 receptor by a specific agonist, or even by endogenous adenosine, 
increases plasma leptin levels in rats (Rice et al., 2000). These results were complemented 
by in vitro studies showing that rat epididymal fat tissue increases leptin secretion in 
response to A1 receptor activation (Rice et al., 2000). Additionally, the activity of the A1 
receptor was shown to increase the release of adiponectin from isolated rat adipocytes in 
response to insulin (Szkudelski et al., 2011). Thus, alterations in A1 receptor expression in 
WAT due to obesity might be involved in alterations in endocrinal function, such as leptin 
and adiponectin release. 
Obesity causes the increased activation and enhanced recruitment of macrophages in 
the adipose tissue, generated by a pro-inflammatory environment that also promotes 
systemic insulin resistance (Chawla et al., 2011; Patsouris et al., 2008). About anti-
inflammatory effect of adenosine, A2B receptor activation in monocytes and macrophages is 
involved in the alternative activation of macrophages, which results in the secretion of anti-
inflammatory cytokines (i.e., IL-10, IL-4) (Csoka et al., 2012; Koscsó et al., 2013). 
Furthermore, Csoka et al (2014) and collaborators found that A2B receptor -/- mice 
exhibited an increase in activated macrophages and inflammatory markers in adipose tissue. 
Moreover, A2B receptor-specific activation blocks the fatty acid-stimulated activation of 
macrophages in vitro (Csóka et al., 2014). Macrophage activation switches the synthesis of 
anti-inflammatory cytokines for pro-inflammatory cytokines such as TNFα or IL-6, which 
are known to promote systemic insulin resistance. Supporting this idea, Johnston-Cox et al 
(2012) found that the expression of A2B receptor mRNA correlates positively with the 
mRNA expression of insulin receptor substrate 2 (IRS2), a key signaling protein in the 
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insulin response, in adipose tissue from obese patients, showing the probable involvement 
of the A2B receptor in insulin sensitization. However, the obesity-induced alterations in 
glucose metabolism were not further impaired in A2B receptor -/- mice (Csóka et al., 2014), 
indicating that A2B receptor signaling might be involved in that mechanism, and proposing 
it as a potential target to improve insulin sensitivity in obesity. Even more, the restitution of 
the expression of A2B receptor in macrophages is enough to protect from inflammation and 
insulin resistance in a HFD–induced obesity model in A2B receptor -/- mice (Johnston-Cox 
et al, 2014). 
 
2.2.2.  Skeletal muscle 
As mentioned above, adenosine receptor activation impairs insulin action in skeletal 
muscle. In contrast to adipose tissue, the probable mechanisms involved in the effects of 
adenosine in skeletal muscle are less clear. According to Crist et al. (2001), in the skeletal 
muscle of rats with HFD-induced obesity there is a reduction in insulin receptor (IR) 
phosphorylation in response to insulin, probably due to an increase in the phosphatase 
activity of protein tyrosine phosphatase 1 (PTP1). Interestingly, the general antagonism of 
adenosine receptors reduced PTP1 activity and increased insulin-stimulated IR 
phosphorylation, indicating a potential role of the adenosine receptors in the impairment of 
the skeletal muscle response to insulin (Crist et al., 2001). Currently, it is unclear which 
adenosine receptors are the primary mediators of this action. A1 receptor -/- mice did not 
exhibit changes in the HFD-induced reduction of glucose uptake in skeletal muscle 
(Johansson et al., 2007), showing that this receptor does not seem to participate in the 
alterations of skeletal muscle glucose homeostasis induced by obesity. Conversely, studies 
have shown that the A2A and A2B receptors are highly expressed in the skeletal muscle of 
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humans, mice and rats (Crist et al., 1998; Johansson et al., 2007; Lynge and Hellsten, 
2000), thus it would expect that the general antagonism of adenosine receptor effect on 
insulin receptor activation could be mediated by one of these receptors.  
It has been reported that A2A receptor -/- mice did not exhibit changes in the skeletal 
muscle response to insulin at basal conditions, showing that this isoform is not involved 
(Figler et al., 2011). In addition, the absence of the A2B receptor resulted in the avoidance 
of the skeletal muscle insulin resistance induced by the injection of a general adenosine 
receptor agonist (Figler et al., 2011). Moreover, in an insulin-resistant diabetic mouse 
model, the specific inhibition of the A2B receptor increased the glucose uptake in skeletal 
muscle induced by insulin (Figler et al., 2011). Thus, upon the general activation of 
adenosine receptors, the A2B receptor could be responsible for the induction of insulin 
resistance in skeletal muscle in obese animals. However, whether endogenous adenosine is 
involved in the activation of this receptor in the skeletal muscle of obese patients is 
unknown. 
 
2.2.3.  Liver 
Though the liver is a central organ in the control of glucose homeostasis and is 
therefore important in the systemic insulin resistance phenomenon (Wilcox, 2005), there 
are few studies regarding the potential role of adenosine receptors in obesity-induced 
insulin resistance in the liver. Similar to skeletal muscle, the general inhibition of adenosine 
receptors improves the HFD-induced impairment response to insulin in the rat’ liver (Crist 
et al., 1998). Studies suggest that the A2B receptor is potentially involved in this effect; 
however, the data are controversial. One study showed that obese mice exhibit an increase 
in A2B receptor expression in the liver. Additionally, the specific activation of the A2B 
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receptor in mice increased liver IRS2 expression and restored the obesity-associated altered 
glucose homeostasis (Johnston-Cox et al., 2012). 
In accordance with these findings, A2B receptor -/- mice showed impaired glucose 
homeostasis, reduced IRS2 expression and increased TNFα expression in the liver 
(Johnston-Cox et al., 2012). However, it has been reported that a specific antagonist of the 
A2B receptor reduced hepatic glucose production in mice and its activation reduced glucose 
tolerance in the whole animal (Figler et al., 2011; Tilg et al., 2011). Additionally, the same 
study showed that single nucleotide polymorphisms in the ADORA2B gene are highly 
correlated with plasma levels of IL-6 and C-reactive protein in diabetic patients (Figler et 
al, 2011), which have been associated with the development of insulin resistance (Blüher et 
al., 2005; Tangvarasittichai et al., 2016). Thus, studies in animal models show that the A2B 
receptor could be involved in the hepatic regulation of glucose homeostasis; however, its 
role in patients with obesity is still unknown. 
The A3 receptor also has a potential role in the liver involvement in glucose 
homeostasis. It has been reported that inosine, an endogenous nucleotide derived from the 
deamination of adenosine (Barankiewicz & Cohen, 1985), through A3 receptor activation, 
can stimulate gluconeogenesis, glycogenolysis and the release of glucose in isolated rat 
hepatocytes (Guinzberg et al., 2006). Furthermore, the same group showed that the 
activation of this receptor by both, adenosine and inosine, is the responsible for the hepatic-
induced hyperglycemia in response to ischemia-reperfusion stress in rats (Cortes et al., 
2009). Thus, due to the increase in adenosine concentrations in obesity, A3 receptor 
activation could be involved in obesity-associated alterations in glucose homeostasis; 
however, whether this adenosine receptor is involved in obesity is still unknown. 
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2.3 Association of adenosine with thermogenesis during obesity 
The imbalance between energy intake and energy expenditure observed in obesity 
gave rise the hypothesis that excess calories could be converted into heat through adaptive 
thermogenesis, a therapeutic approach to obesity. Thermogenesis involves the loss of 
energy as heat (energy expenditure) by coordinated mechanisms, such as shivering and 
non-shivering in response to low environmental temperature or diet, in order to maintain 
the core temperature (Daanen and Van Marken Lichtenbelt, 2016; Celi et al., 2015). 
Shivering thermogenesis (ST) refers to the increased heat production  caused by rhythmic 
skeletal muscle contractions while non-shivering thermogenesis (NST) involves heat 
production by chemical reactions in the mitochondria of brown adipocytes, through the 
activation of uncoupling protein-1 (UCP1) activation, stimulated by the sympathetic 
nervous system (SNS) or by non-adrenergic pathways, such as natriuretic peptides, FGF21, 
bile acids or irisin, among others, which induce heat production through uncoupling 
respiration from ATP synthesis (Blondin et al., 2015; Villarroya and Vidal-Puig, 2013).  
 
2.3.1 Thermogenesis in adipose tissue 
In newborns, BAT is located in the cervical, interscapular, axillary, perirenal and 
paraaortic areas (Park et al, 2016). In adults, the detection of the glucose uptake, detected 
by positron emission tomography combined with computed tomography (PET–CT), has 
demonstrated the presence of active BAT depots located in the supraclavicular, neck, 
paravertebral and perirenal regions (Peng et al, 2015; Izzi-Engbeaya et al, 2014). These 
BAT depots in adults are composed of two types of cells, classical (brown) and brown 
adipocyte-like (beige) cells. Beige adipocytes are brown-like white adipocytes with a 
characteristic genetic expression pattern that during exercise, cold exposure or stimulation 
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with several molecules (i.e., irisin, FGF21, follistatin) induced an increase in UCP1 protein 
levels, and show thermogenic properties, in a process termed “fat browning” (Thuzar and 
Ho, 2016; Rodriguez et al, 2015). Beige depots are located mainly in the inguinal and 
epididymal WAT (Dempersmier and Sul, 2015; Park et al., 2014).  
It is noteworthy that the different varieties of adipose tissue come from different 
precursors. Classical brown adipocytes originate from the myogenic lineage of Myf5-
positive, stem cell antigen-1-positive and paired box 7-positives cells (Myf5+/Sca-
1+/Pax7+) of the dermomyotome, a common progenitor of skeletal muscle and dermis, 
while all white adipocytes originate from a Myf5-negative (Myf5-) precursor 
(Dempersmier et al, 2015). Meanwhile, beige adipocytes come from a heterogeneous 
population of cells (Mulya and Kirwan, 2016). Depending on different metabolic factors, 
beige adipocytes can be derived from Myf5- lineage precursor cells and from Myf5+ cells 
or smooth muscle-like precursors positive for myosin heavy chain 11 (Myh11) (Long et al., 
2014; Sanchez-Gurmaches and Guertin, 2014). However, it has been reported that 
adrenergic stimulation increases the amount of beige adipocyte cells in WAT from adult 
humans and rats (Frontini et al, 2013; Himms-Hagen et al, 2000). Since these cells do not 
present pre-existing proliferation precursors (Frontini et al, 2013) and have reduced 
proliferative indexes (Himms-Hagen et al, 2000), these findings support the idea that the 
increase of beige adipocytes is mainly due to white into brown transdifferentiation, 
phenomenon known as ‘browning’ (Cinti S, 2016). 
BAT is characterized as a highly vascularized tissue, innervated by the SNS and is 
highly oxidative due to the presence of multilocular fat cells with abundant mitochondria 
aimed to produce heat (adaptative thermogenesis) through the utilization of glucose and 
lipids (Lizcano and Vargas, 2016). The activation of both brown and beige fat involves 
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input from the SNS through β-adrenergic receptors, which trigger PPARγ coactivator 1α 
(PGC1α) and a cascade of intracellular changes via cyclic AMP (cAMP). This results in the 
increased lipolysis of intracellular triglycerides, raising FFA levels that are used by 
uncoupling protein 1 (UCP1) located in the inner mitochondrial membrane, acting as a 
H+/fatty acid symporter (Peng et al., 2015; Park et al., 2014). Through this, mechanism the 
uncoupling of mitochondrial respiration is initiated, separating oxidative phosphorylation 
from ATP synthesis and resulting in a futile cycle that generates heat instead of ATP (non-
shivering thermogenesis). To compensate for the lack of ATP adrenergic stimulation 
enhances BAT glucose uptake and glycolysis (Albert et al., 2016; Labbé et al., 2016). Thus, 
the ability of beige adipocytes to increase energy expenditure in order to produce heat by 
the stimulation of the SNS or the administration of β-adrenergic receptor agonists, such as 
chronic cold exposure, exercise or diet, is a promising target to evaluate in obesity. 
 
2.3.2 Role of adenosine in thermogenesis during obesity 
It has been reported that thermogenic tissue is inversely related to body mass index 
and body fat percentage (Granneman, 2015; Peng et al., 2015; Vosselman et al., 2015). 
Nevertheless, there are multiple environmental and metabolic factors involved in BAT 
activation and the browning of WAT. Browning implies morphologic and molecular 
changes, such as the size reduction, mitochondriogenesis and multilocularization of lipid 
droplets (Giordano et al., 2016; van der Lans et al., 2013). Thus, triggering this 
thermogenic profile in WAT could be an excellent approach to reducing the obesity-
associated deleterious effects. It is thought that adenosine, through the A2A receptor, 
increases lipolysis and NST in brown and white human adipocytes; moreover, it has been 
reported that the concentration of adenosine required to achieve the half-maximal activation 
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of lipolysis in primary human brown and white adipocytes is 3 nmol/l and 1170 nmol/l, 
respectively (Gnad et al, 2014). Nevertheless, it has been also observed that adenosine 
inhibits lipolysis in WAT through A1 receptor activation (Johansson et al, 2008). On the 
one hand, this opposite effect could be explained by the differential expression of the 
adenosine receptors in the adipocytes, since the A1 receptor is highly expressed in white 
adipocytes while the expression of the A2A receptor is significantly higher in BAT than in 
WAT (Gnad et al, 2014). On the other hand, this phenomenon could be explained by 
different local concentrations of adenosine in each tissue. 
The hypertrophy, hyperplasia, and inflammation of WAT in obesity are factors 
involved in the reduction of thermogenic adipose tissue (Shimizu et al, 2014; Polyak et al, 
2016). In this context, there is a report showing that HFD-induced BAT inflammation in 
mice is accompanied by the increased expression of lipogenic enzymes, which results in the 
‘whitening’ of BAT (i.e., BAT to WAT). This process is characterized by an increased 
expression of lipogenic enzymes and morphologicals alterations such as the coalescence of 
lipid droplets and elevated mitochondrial ROS production (Polyák et al, 2016; Shimizu et 
al, 2014). As mentioned before, obesity is associated with a chronic inflammatory state. It 
has been reported that one of the pro-inflammatory cytokines increased during obesity is 
the chemokine fractalkine (CX3CL1), which is a chemoattractant synthesized by 
adipocytes and mediates macrophage adhesion to WAT and BAT during the development 
of obesity through the activation of its specific receptor, CX3CR1, which is highly 
expressed on monocytes and T cells in humans (Polyák et al., 2016, 2014; Jung et al., 
2000). This whitening of BAT during obesity could increase the lipogenic profile. 
Interestingly, it has been observed that in neuronal and microglial cells, fractalkine is 
capable of releasing adenosine as a neuroprotective response (Lauro, 2015) only in the 
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presence of a functional A1 receptor (Lauro et al., 2010, 2008). Thus, it is possible that, as 
occurs in neuronal and microglial cells, the increased fractalkine-CX3CR1 binding during 
obesity could be associated with the increased extracellular adenosine concentrations and 
A1 receptor activation also seen in obesity. 
Due to the high vascularization of BAT, the endothelial dysfunction observed in 
obesity could enhance this whitening of BAT (Elias et al, 2012). In fact, it has been 
reported that the deletion of the Vegfa gene in the adipose tissue of non-obese mice resulted 
in BAT whitening (Shimizu et al, 2014); therefore, the improvement of vascular function in 
BAT could help restore thermogenic function during obesity. Adenosine is known to play 
an important role in vascular function; for example, it has been reported that the treatment 
of a melanoma mouse model with an A2B receptor agonist enhanced Vegfa expression and 
vessel density in tumors (Sorrentino et al, 2015). Moreover, another study showed that the 
A2B receptor increased the production of VEGF-A via cAMP-PKA-CREB in human 
vascular endothelial cell line 1 (HMEC-1) (Du et al., 2015). Thus, adenosine may be 
playing a role in the modulation of BAT during obesity. However, more studies are 
necessary. 
In contrast to BAT, which constitutively expresses high levels of thermogenic genes 
such as UCP1, beige adipocytes require constant stimulation for the induction of 
thermogenic genes (Wu et al., 2013; Petrovic et al., 2010).  In fact, a recent study 
demonstrated the reversible thermogenic profile of beige adipocytes (Park, et al 2014). 
Thus, the plasticity of adipose tissue to change its metabolic profile and increase energy 
expenditure in a stimulus-dependent manner is currently one of the main approaches to 
reverse the obesity and is the focus of numerous studies (Contreras et al., 2016; Ramseyer 
and Granneman, 2016; Liu et al., 2015.; Lo and Sun, 2013). 
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Finally, recent studies in animals have indicated the involvement of the A2A receptor 
in the browning of WAT. It has been reported that cold- or β-adrenergic agonist-induced 
activation of sympathetic signaling, which is associated with browning, is attenuated by the 
ablation of the A2A receptor (Dempersmier and Sul, 2015). Moreover, the direct injection of 
lentiviral vectors expressing the A2A receptor into WAT depots induced the formation of 
beige adipocytes in an HFD-induced obese mouse model (Gnad et al, 2014), and its specific 
activation in BAT and WAT increased the expression of thermogenic markers, including a 
7-fold increase of UCP1 in WAT, reflecting the browning of WAT (Gnad et al, 2014). 
Additionally, there is a report showing that A2B receptor activation increases the levels of 
C/EBPβ, IRF4, and PPARγ in adipose tissue (Csóka et al 2014), which are nuclear factors 
associated with the formation of BAT in transgenic mice overexpressing PPARγ in adipose 
tissue (Zhou et al, 2014). Thus, it seems that adenosine could be involved in the activation 
of adaptative thermogenesis in BAT and in the induction of beige adipocyte formation, 
indicating that the adenosine or adenosine receptor-mediated browning of WAT is a 
potential probable novel target in the treatment of obesity. 
 
3. Adenosine as a therapeutic target 
Because of all the effects attributed to adenosine, the therapeutic response could 
vary according to obesity state, tissue and adenosine receptor involvement. As described 
above, the effect of adenosine depends on the type and number of receptors expressed, 
modulating the potency of the effect and on the expression of enzymes that synthesize, 
degrade or transport adenosine, which results in specific microdomain adenosine 
concentrations that activate the receptors in both autocrine and paracrine manners 
(Fredholm et al, 2014). 
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Few studies on obesity have determined the concentration of adenosine in plasma or 
adipose tissue (Table 2). Neither a proposal for the metabolic consequences of an elevated 
adenosine concentration in obese patients is at present proposed. When the concentration of 
adenosine during obesity has been determined by different methodologies and in various 
organs, an approximate 1.5-fold increase compare to the normal state has been observed, 
which seems to show that the adenosine concentration rises systemically during obesity. 
Though the adenosine concentration observed in normal plasma could activate the A1, A2A 
and A3 receptors, this concentration is not able to activate A2B (Table 3) (Fredholm, 2014; 
Funaya et al, 1997). Nevertheless, Patel et al (2003) described the activation of the A2B 
receptor with a 2 µmol/l concentration of adenosine mediated by pH variations. Even 
though the adenosine concentration may increase by 5-fold in pathological conditions 
(Fredholm, 2014), specific alterations in the synthesis, degradation or transport of 
adenosine in the tissue could increase or reduce the local adenosine concentration and 
activate the adenosine receptors specifically expressed in that tissue. 
In summary (Figure 3), first, the activation of the A2B receptor could be necessary to 
avoid obesity, since its activation results in the inhibition of adipogenesis and improves 
insulin resistance. Second, treatment with the adenosine receptor antagonist BWA1433 
improved glucose tolerance, increasing glucose uptake in muscle and liver and reducing it 
in adipose tissue, but also inhibited on adiponectin secretion, promoting insulin resistance 
(Crist et al, 1998; Xu et al, 1998). These results highlight the differential adenosine receptor 
pattern among tissues, however, whether this effect is produced by the inactivation of the 
A1 or A2B receptors is still unclear. In WAT, the expression of the A2A receptor is lower 
than that of the A1 receptor, and it is therefore expected that the main adenosine effects 
would be the improvement of insulin response in WAT and the inhibition of lipolysis, 
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promoting weight gain. Third, the activation of the A2A receptor is involved in the 
browning process, resulting in increased lipolysis and leading to a reduction in adipocyte 
size but also to the release of FFA into the blood, which could cause other side effects. 
Nevertheless, the treatment with a specific tissue-directed A2A receptor agonist could be a 
pharmacological approach to reverse the obesity-associated adipose tissue increases and 
comorbidities, along with increased exercise and diet regulations to reduce the levels of 
FFA in blood. 
 
4. Concluding remarks 
The pharmacological modulation of the adenosine receptors could be beneficial in 
the obesity treatment. Since adenosine is involved in the adipogenesis, insulin sensitivity 
and thermogenesis activation, an adequate strategy could allow to reduce obesity 
prevalence. Adenosine treatment as a unique therapy will be difficult to implement due to 
the diverse systemic effects of this nucleoside. Thus, it is necessary to dissect the tissue-
specific effects to prevent any secondary consequences. In conclusion, in order to revert 
obesity and its comorbidities, the modulation of adenosine receptors seems to be an 
attractive approach.  
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Table 1. Tissue specific adenosine receptor effects involves on obesity 
Receptors Activation Inactivation Effect Tissue Reference 
A1 NA  Lipolysis inhibition 
Adipocytes primary culture from 
male mouse 
Johansson et al, 
2007 
A1 
Partial agonist 
ARA  Reduces insulin resistance Whole-body of male obese ZF rats 
Schoelch et al., 
2004 
A1 Agonist CPA  Increases leptin secretion 
Adipocytes from epididymal fat 
tissue of male Sprague Dawley rats Rice et al., 2000 
A1   
Non-selective Antagonist 
BWA1433 Reduces glucose uptake Adipose tissue of ZF rats  Crist et al., 1998 
A1  Antagonist DPCPX 
Inhibition of 
adiponectin secretion 
Epididymal fat tissue from male 
Wistar rats 
Szkudelski et 
al., 2011 
A2A Agonist PSB-0777  Increase lipolysis 
Inguinal WAT and gonadal fat 
depots from mouse  
Gnad et al., 
2014 
A2B 
Agonist BAY 60-
6583  Restores IRS-2 levels 
Liver of WT mice after 16 weeks 
HFD 
Johnston-Cox et 
al., 2012 
A2B 
Agonist BAY 60-
6583  Inhibits Adipogenesis 
Stromal Vascular Cell from mouse 
inguinal adipose tissue 
Eisenstein et al, 
2014 
A2B  
Non-selective Antagonist 
BWA1433 Increase glucose uptake 
Gastrocnemius and soleus muscles 
from ZF rats Crist et al., 1998 
A2B  A2B KO mice 
Enhance adipose tissue 
inflammation Epididymal adipose tissue 
Csóka et al., 
2014 
A2B  Antagonist ATL-801  Increases glucose uptake 
Skeletal muscle and brown adipose 
tissue from diabetic mice  
Figler et al., 
2011 
A2B  A2B KO mice 
Elevate TNF-α, IL-6 and 
CD11b levels Liver from KO mice with HFD 
Johnston-Cox et 
al., 2012 
A3 Agonist IB-MECA  Stimulate glucose release  
Isolated hepatocytes from Male 
Wistar rats 
Guinzberg et al., 
2006 
Legend for Table 1 in the next page. 
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Legend for Table 1 
 
NA:l-noradrenaline hydrochloride; ARA: [1S,2R,3R,5R]-3-methoxymethyl-5-[6-(1-[5-trifluoromethyl-pyridin-2-yl]pyrrolidin-3-[S]-
ylamino)-purin-9-yl]cyclopentane-1,2-diol; CPA: N6-cyclopentyladenosine; BWA1433: 1,3-dipropyl-8-(p-acrylic) phenyl xanthine; 
DPCPX: 8-cyclopentyl-1,3-dipropylxanthine; PSB-0777: 4-[2-[(6-Amino-9-b-D-ribofuranosyl-9H-purin-2-
yl)thio]ethyl]benzenesulfonic acid ammonium salt; BAY 60-6583: 2-[[6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]-2-
pyridinyl]thio]-acetamide; IB-MECA:1-Deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-β-D-
ribofuranuronamide; KO: knockout; ATL-801:N-[5-(l-cyclopropyl-2,6-dioxo-3-propyl-7H-purin-8-l)pyridin-2-yl]-N-ethylpyridine-3-
carboxamide; IRS-2:insulin receptor substrate 2; TNF-α: tumor necrosis factor alpha; IL-6: interleukin 6; CD11b: cluster of 
differentiation molecule 11B; ZF: Zucker fatty; WAT: white adipose tissue; WT: wild type; HFD: high-fat diet. 
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Table 2. Adenosine concentration in obese human patients. 
Sample Adenosine concentration Significance Fold changes 
(obese/control) 
Methods of 
measurement 
References 
Control Obese 
Adipose tissue 
(pmol/g wet weight) 0.42 ± 0.06 0.67 ± 0.14 P = 0.06 ~1.59 Radioimmunoassay  Kaartinen et al, 1991 
Plasma 
(µmol/l/mg protein) 1.2 ± 0.1 1.8 ± 0.2 P < 0.05 ~1.5 
High performance 
liquid chromatograph 
system 
Escudero et al, 2012  
Plasma 
(µmol/l) 
0.062 ± 
0.003  
  Radioimmunoassay Funaya et al, 1997 
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Table 3. Half-concentration activation of human adenosine receptor 
Receptor EC50 or Ki (µmol/l) Model Method Reference 
A1 0.31 
CHO cells transfected with 
recombinant human A1 receptor 
cAMP determination Fredholm et al., 2001 
A2A 0.73 
CHO cells transfected with 
recombinant human A2A receptor 
cAMP determination Fredholm et al., 2001 
A2B 
2 HEK-293 transfected with 
recombinant human A2B receptor 
Microphysiometry 
(pH variations) Patel et al., 2003 
23.5 CHO cells transfected with 
recombinant human A2B receptor 
cAMP determination Fredholm et al., 2001 
15 VA13 cells cAMP determination Bruns 1980 
A3 0.29 
CHO cells transfected with 
recombinant A3 receptor 
cAMP determination Fredholm et al., 2001 
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Fig 1. Adenosine effects mediated by its receptor on obesity. Adenosine could act 
mediated A1, A2A, A2B and A3 receptors at different levels, with a variety of effects. 
The activation of A1 receptor will increase adipogenesis, reduce lipolysis and 
insulin resistance and increase leptin secretion, but the inactivation will reduce 
adiponectin secretion. The activation of A2A receptor will increase lipolysis. A2B 
receptor activation will reduce insulin resistance, increase IRS-1 expression in liver, 
ad will reduce adipogenesis on preadipocytes, meanwhile, the inactivation of this 
receptor will increase inflammation and glucose uptake in muscle. Finally, A3 
receptor activation increases hepatic glucose release.  
 
Fig 2. Involvement of A1 receptor in the adipocyte during obesity. A1 receptor (A1R) act 
as insulin sensitizer, increasing the effect of glucose uptake and adiponectin release 
mediated by insulin receptor (IR). On the other hand, A1R is able to increase leptin 
release and inhibit lipolysis. Insulin also decrease lipolysis in the adipocyte. Leptin 
has lipolytic effect mediated adenylate cyclase/Gi protein, inhibiting antilipolysis 
adenosine effect. Lipolysis inhibition and increased glucose uptake will increase 
triglyceride depots. 
 
Fig 3. Adenosine receptor association in obesity during adipogenesis and 
thermogenesis. Different preadipocytes origins will produce lipogenic and 
thermogenic tissue, as withe and brow adipose tissue, respectively, present at 
normal state (lean). During obesity, preadipocite will increase adipogenesis, 
producing a hypertrophy and hyperplasia of the white adipose tissue. Also, obesity 
is able to produce inflammation of the brown adipose tissue, producing the 
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‘whitening’. It is described, that some adipocytes are able to transdifferentiate to 
beige adipose tissue (browning). Mediated the increase of thermogenic adipose 
tissue (purple arrow) is possible to reduce obesity. Adenosine receptor (red arrows) 
can participate activating (A1 receptor) or inhibiting (A2B receptor) adipogenesis, 
increasing whitening (A1 receptor) or rising browning (A2A receptor).  Nevertheless, 
the production of original brow adipose tissue from white adipose tissue and the 
transformation of the beige adipose tissue to white adipose tissue are unknown. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
